References
1. M.T. Hayes. Parkinson’s disease and Parkinsonism. Am. J. Med.
2019;132:802–807.
2. P.A. Lewis, J.E. Spillane, Chapter 3 Parkinson’s disease, in: P.A.
Lewis, J.E. Spillane (Eds.). The molecular and clinical pathology of
neurodegenerative disease. Academic Press; 2019. pp. 83–121.
3. C. Raza, R. Anjum, N.U.A. Shakeel. Parkinson’s disease: mechanisms,
translational models and management strategies. Life Sci. 2019; 226
:77–90.
4. Zou YM, Liu J, Tian ZY, Lu D, Zhou YY. Systematic review of the
prevalence and incidence of Parkinson’s disease in the People’s Republic
of China. Neuropsychiatr Dis Treat. 2015;11:1467–72.
5. Finberg JPM. The discovery and development of rasagiline as a new
anti-Parkinson medication. J Neural Transm (Vienna). 2020
Feb;127(2):125-130.
6. Avila A, Caballol N, Martín-Baranera M, Gómez-Ruiz I, Balagué-Marmaña
M, Planas-Ballvé A, Cardona X. Rasagiline and safinamide as a
dopamine-sparing therapy for Parkinson’s disease. Acta Neurol Scand.
2019 Jul;140(1):23-31.
7. Thébault JJ, Guillaume M, Levy R. Tolerability, safety,
pharmacodynamics, and pharmacokinetics of rasagiline: a potent,
selective, and irreversible monoamine oxidase type B inhibitor.
Pharmacotherapy. 2004 Oct;24(10):1295-305.
8. Chen JJ, Swope DM. Clinical pharmacology of rasagiline: a novel,
second-generation propargylamine for the treatment of Parkinson disease.
J Clin Pharmacol. 2005 Aug;45(8):878-94.
9. Azilect prescribing information, 2018. Available at: